Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin

AbstractRationale:Dapagliflozin (a sodium-glucose cotransporter-2 [SGLT2] inhibitor) represents the most recently approved class of oral medications for the treatment of type 2 diabetes. Dapagliflozin lowers plasma glucose concentration by inhibiting the renal reuptake of glucose in the proximal ren